Cervical Lesion Articles & Analysis
12 news found
With that, DYSIS has been awarded with the 2021 Frost & Sullivan New Product Innovation Award — North American Smart Colposcopy for Cervical Lesion ...
In the fourth quarter, we completed enrollment of REVEAL2, our second global Phase 3 clinical trial of VGX-3100 for cervical pre-cancer. In addition, we recently completed enrollment in our Phase 1/2 clinical trial for INO-3107, our DNA immunotherapy for the rare disease recurrent respiratory papillomatosis (RRP), which received orphan drug designation from the U.S. ...
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year ...
Specifically, INOVIO's lead therapeutic candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. ...
Specifically, INOVIO's lead therapeutic candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. ...
VGX-3100 is in Phase 3 clinical trials to study the immunotherapy candidate for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL) and in Phase 2 clinical trials to study the immunotherapy candidate for the treatment of anal and vulvar HSIL. ...
This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA® 5PSP device. ...
INOVIO Fourth Quarter and Year-End 2020 Highlights On March 1, 2021, INOVIO announced that it met primary and secondary efficacy endpoints among all evaluable subjects for the REVEAL 1 (Randomized Evaluation of VGX-3100 and Electroporation for the treatment of Cervical HSIL) trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, ...
It is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus (HPV-16 and HPV-18). "As we advance our DNA medicines platform, we are always looking for ways to drive innovation with our own technology or that of a creative and ...
Hard Tissue Applications: Skulls - sinus, nasal, bulla, ears, brain, oncology, trauma Orthopedics - stifles, elbows, hips, carpus/tarsus, angular limb deformities, OCD, cartilage lesions, fractures Dentistry Spine - cervical, thoracic, lumbar Soft Tissue Applications: Tumors, foreign bodies Thorax - lungs, heart Blood vessels, met checks Abdomen ...
Human papilloma virus (HPV) infection has been recognized as the necessary cause of cervical intraepithelial neoplasia (CIN1/2/3) and cervical cancer. HPV infection is the most common sexually transmitted disease, affecting about 400 million women worldwide. Persistent HPV infection can lead to CIN2/3 and then to cervical cancer. Worldwide, ...
GARDASIL is approved in the U.S. for use in girls and young women 9 through 26 years of age for the prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. ...